Skip to main content
. 2014 Jun 1;29(5):215–220. doi: 10.1089/cbr.2014.1610

Table 1.

Correlation Between Clinicopathogical Features and Lin28B Expression in 190 Breast Cancer Cases

    Lin28B expression        
Clinicopathological features na(%) Negative (%) Positive (%) χ2 pb r pc
All cases 190 (100) 107 (56.3) 83 (43.7)        
Age       0.021 0.884    
 ≤46.5 95 (50.0) 54 (28.4) 41 (21.6)        
 >46.5 95 (50.0) 53 (27.9) 42 (22.1)        
Menopausal status       0.229 0.632    
 Premenopausal 120 (63.2) 66 (34.7) 54 (28.4)        
 Postmenopausald 70 (36.8) 41 (21.6) 29 (15.3)        
Tumor size (cm)       4.729 0.094    
 <2 53 (27.9) 31 (16.3) 22 (11.6)        
 2–5 123 (64.7) 72 (37.9) 51 (26.8)        
 >5 14 (7.4) 4 (2.1) 10 (5.3)        
Histological differentiation       13.790 0.001 0.216 0.003
 Well 61 (32.1) 39 (20.5) 22 (11.6)        
 Moderate 81 (42.6) 52 (27.4) 29 (15.3)        
 Poor 48 (25.3) 16 (8.4) 32 (16.8)        
TNM staging       9.213 0.002 0.220 0.002
 I–II 97 (51.1) 65 (34.2) 32 (16.8)        
 III–IV 93 (48.9) 42 (22.1) 51 (26.8)        
Metastatic lymph nodes       30.996 <0.0001 0.359 <0.0001
 0 72 (37.9) 59 (31.1) 13 (6.8)        
 1–3 45 (23.7) 18 (9.5) 27 (14.2)        
 ≥4 73 (38.4) 30 (15.8) 43 (22.6)        
ER       0.160 0.899    
 Negative 86 (45.3) 48 (25.3) 38 (20.0)        
 Positive 104 (54.7) 59 (31.1) 45 (23.7)        
PR       2.307 0.129    
 Negative 92 (48.4) 57 (30.0) 35 (18.4)        
 Positive 98 (51.6) 50 (26.3) 48 (25.3)        
Her-2       1.264 0.261    
 Negative 147 (77.4) 86 (45.3) 61 (32.1)        
 Positive 43 (22.6) 21 (11.1) 22 (11.6)        
Ki67       13.268 <0.0001 0.037 0.677
 Negative 76 (40.0) 55 (28.9) 21 (11.1)        
 Positive 92 (60.0) 52 (27.4) 62 (32.6)        
Subtype       20.450 <0.0001    
 Luminal A 52 (27.4) 41 (21.6) 11 (5.8)        
 Luminal B 59 (31.1) 22 (11.6) 37 (19.5)        
 Her-2 overexpression 29 (15.3) 14 (12.8) 15 (7.9)        
 Basal like 50 (26.3) 30 (15.8) 20 (10.5)        
a

Number of cases in each group.

b

p for χ2 test.

c

p for Spearman rank correlation.

d

Postmenopausal status for natural menopause.

ER, estrogen receptor; PR, progesterone receptor; TNM, tumors, lymph nodes, and metastases.

HHS Vulnerability Disclosure